Halting the Epidemic of Addiction and Loss Act of 2023 or the HEAL Act of 2023
This bill requires the Department of Health and Human Services (HHS) to ensure that references in its grant programs to opioid overdose reversal agents are inclusive of any such agents that have been approved by the Food and Drug Administration (FDA).
Specifically, HHS must ensure that regulations, guidance, and other documents for grant programs that include references to opioid overdose reversal agents (e.g., naloxone) encompass any opioid overdose reversal agent that has been approved by the FDA. HHS must also update such references with respect to materials that were previously issued for State Opioid Response Grants, Tribal Opioid Response Grants, and Programs of Regional and National Significance for substance use disorder prevention.
[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4007 Introduced in House (IH)]
<DOC>
118th CONGRESS
1st Session
H. R. 4007
To ensure references to opioid overdose reversal agents in grant
programs of the Department of Health and Human Services are not limited
to naloxone.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 12, 2023
Mr. Armstrong (for himself and Mr. Tonko) introduced the following
bill; which was referred to the Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To ensure references to opioid overdose reversal agents in grant
programs of the Department of Health and Human Services are not limited
to naloxone.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Halting the Epidemic of Addiction
and Loss Act of 2023'' or the ``HEAL Act of 2023''.
SEC. 2. REFERENCES TO OPIOID OVERDOSE REVERSAL AGENTS IN HHS GRANT
PROGRAMS.
(a) In General.--The Secretary of Health and Human Services shall
ensure that, whenever the Department of Health and Human Services
issues a regulation, guidance, or other document for any grant program
addressing opioid misuse and use disorders, any reference to an opioid
overdose reversal agent (such as a reference to naloxone) is inclusive
of any opioid overdose reversal agent that has been approved or
otherwise authorized for use by the Food and Drug Administration.
(b) Existing References.--
(1) Update.--Not later than the end of calendar year 2023,
the Secretary of Health and Human Services shall update all
references described in paragraph (2) to be inclusive of any
opioid overdose reversal agent that has been approved or
otherwise authorized for use by the Food and Drug
Administration.
(2) References.--A reference described in this paragraph is
any reference to an opioid overdose reversal agent (such as
naloxone) in any regulation, guidance, or other document of the
Department of Health and Human Services that--
(A) was issued before the date of enactment of this
Act; and
(B) is for--
(i) the grant program for State and Tribal
response to opioid use disorders under section
1003 of the 21st Century Cures Act (42 U.S.C.
290ee-3 note; commonly referred to as ``State
Opioid Response Grants'' and ``Tribal Opioid
Response Grants''); or
(ii) the grant program for priority
substance use disorder prevention needs of
regional and national significance under
section 516 of the Public Health Service Act
(42 U.S.C. 290bb-22).
<all>
Introduced in House
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line